Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 105 points (0.6%) at 16,554 as of Tuesday, April 22, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,226 issues advancing vs. 749 declining with 155 unchanged. The Health Care sector currently sits up 2.7% versus the S&P 500, which is up 0.6%. Top gainers within the sector include Allergan ( AGN), up 15.7%, Intercept Pharmaceuticals ( ICPT), up 14.4%, Shire ( SHPG), up 5.7%, Valeant Pharmaceuticals International ( VRX), up 5.6% and Vertex Pharmaceuticals ( VRTX), up 4.6%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Pfizer ( PFE) is one of the companies pushing the Health Care sector higher today. As of noon trading, Pfizer is up $0.36 (1.2%) to $31.22 on average volume. Thus far, 14.6 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.8 million shares. The stock has ranged in price between $30.85-$31.25 after having opened the day at $30.85 as compared to the previous trading day's close of $30.86. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $193.4 billion and is part of the drugs industry. Shares are up 0.8% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.